Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Fidaxomicin is approved by both the FDA and EMA for the treatment of Clostridioides difficile infection (CDI), including recurrent cases. The drug is recommended in several guidelines as first-line therapy for Clostridioides difficile infection (CDI) (initial) and Clostridioides difficile infection (CDI) (recurrent) due to its reduced risk of recurrence compared to vancomycin, and is bro…